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A novel, evolutionarily conserved protein phosphatase complex
involved in cisplatin sensitivity
Abstract
Using a combination of tandem affinity purification tagging and mass spectrometry, we characterized a
novel, evolutionarily conserved protein phosphatase 4 (PP4)-containing complex (PP4cs, protein
phosphatase 4, cisplatin-sensitive complex) that plays a critical role in the eukaryotic DNA damage
response. PP4cs is comprised of the catalytic subunit PP4C; a known regulatory subunit, PP4R2; and a
novel protein that we termed PP4R3. The Saccharomyces cerevisiae PP4R3 ortholog Psy2 was
identified previously in a screen for sensitivity to the DNA-damaging agent and anticancer drug
cisplatin. We demonstrated that deletion of any of the PP4cs complex orthologs in S. cerevisiae elicited
cisplatin hypersensitivity. Furthermore human PP4R3 complemented the yeast psy2 deletion, and
Drosophila melanogaster lacking functional PP4R3 (flfl) exhibited cisplatin hypersensitivity, suggesting
a highly conserved role for PP4cs in DNA damage repair. Finally we found that PP4R3 may target
PP4cs to the DNA damage repair machinery at least in part via an interaction with Rad53 (CHK2).
A Novel, Evolutionarily Conserved Protein
Phosphatase Complex Involved in Cisplatin
Sensitivity*□S
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Using a combination of tandem affinity purification tag-
ging and mass spectrometry, we characterized a novel,
evolutionarily conserved protein phosphatase 4 (PP4)-
containing complex (PP4cs, protein phosphatase 4, cis-
platin-sensitive complex) that plays a critical role in the
eukaryotic DNA damage response. PP4cs is comprised of
the catalytic subunit PP4C; a known regulatory subunit,
PP4R2; and a novel protein that we termed PP4R3. The
Saccharomyces cerevisiae PP4R3 ortholog Psy2 was
identified previously in a screen for sensitivity to the DNA-
damaging agent and anticancer drug cisplatin. We dem-
onstrated that deletion of any of the PP4cs complex or-
thologs in S. cerevisiae elicited cisplatin hypersensitivity.
Furthermore human PP4R3 complemented the yeast psy2
deletion, and Drosophila melanogaster lacking functional
PP4R3 (flfl) exhibited cisplatin hypersensitivity, suggest-
ing a highly conserved role for PP4cs in DNA damage
repair. Finally we found that PP4R3 may target PP4cs to
the DNA damage repair machinery at least in part via an
interaction with Rad53 (CHK2). Molecular & Cellular
Proteomics 4:1725–1740, 2005.
Reversible protein phosphorylation is a highly conserved,
essential regulatory mechanism involved in a host of cellular
processes. Yet, while the phosphorylation of regulatory mol-
ecules by kinases has been studied intensively, their subse-
quent dephosphorylation is much less well understood. In
eukaryotes, dephosphorylation on serine/threonine residues
is effected by two distinct groups of functionally diverse phos-
phatases, the phosphoprotein M (represented by a sole mem-
ber in higher eukaryotes, PP2C) and PPP1 families (1). Within
the much larger PPP class, a common catalytic domain (of
280 aa) is highly conserved, whereas the N and C termini are
more divergent and further separate the PPP proteins into
subfamilies. A number of distinct PPP subfamilies have thus
been characterized (PP1, PP2A, PP2B, PP5, and PP7; Ref. 2)
based on sequence homology, associated regulatory sub-
units, sensitivity to different types of chemical inhibitors, and
metal ion requirements. A major PPP subfamily that plays a
variety of critical roles in a multitude of physiological pro-
cesses is the PP2A-type phosphatases, PP2AC (the catalytic
subunit of PP2A; human gene names PPP2CA and PPP2CB),
PP4C (gene name PPP4C, formerly known as PPX), and
PP6C (PPP6C; Ref. 3).
PP2A often functions as a standard trimeric complex with a
catalytic (C) subunit (encoded by two genes in mammals)
associated with one of many regulatory (or B) subunits via one
of two adaptor (A) molecules (4, 5). The regulatory and adap-
tor subunits are thought to confer substrate specificity to the
complex (5).
In contrast to PP2A, the supramolecular architecture and
subunit composition of PP4 multiprotein complexes remains
largely unknown. Two mammalian PP4 regulatory subunits
were previously identified (here termed PP4R1 and PP4R2,
gene names PPP4R1 and PPP4R2; Refs. 6 and 7). Although
PP4R1 shares some sequence homology with the PP2A
adaptor proteins (PPP2R1A and PPP2R1B), it does not bridge
PP4C and PP4R2; PP4R1 and PP4R2 display mutually exclu-
sive PP4C interactions (Refs. 6 and 7; and see below). Other
PP4C-interacting partners have also been reported (e.g. Refs.
8 and 9), but whether these proteins represent bona fide
regulatory subunits or phosphatase substrates and how these
binding proteins may affect PP4 activity are unclear.
To gain a better understanding of the composition, func-
tion, and regulation of PP4, we systematically analyzed mam-
malian and yeast PP4C-interacting proteins. In doing so, we
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Supplemental Material can be found at: 
were able to characterize several different mutually exclusive
PP4C-containing complexes and identified a novel, evolution-
arily conserved PP4C binding partner (which we termed
PP4R3) that assembles into a complex with PP4C and
PP4R2. Interestingly deletion of the yeast PP4R3 ortholog
PSY2 was demonstrated previously to elicit hypersensitivity
to the DNA damage-inducing drug cisplatin (10). We found
that deletion of the other components of the yeast
PP4CPP4R2PP4R3 complex also yielded cisplatin hyper-
sensitivity; therefore we termed this complex PP4cs (protein
phosphatase 4, cisplatin-sensitive; see below).
Platinum-based anticancer agents such as cisplatin and
carboplatin display a broad range of activities against solid
tumors (11, 12). However, the response to platinum-induced
DNA damage is not well understood; multiple intracellular
signaling pathways are clearly involved in DNA repair (12). A
common problem with cisplatin-based cancer therapies is
resistance to cisplatin. A better understanding of the cellular
processes and effectors involved in the response to cisplatin
treatment may thus improve our ability to treat cancer.
EXPERIMENTAL PROCEDURES
Plasmids and Yeast Strains—pcDNA3-flagA was a kind gift from
Dr. S. Morino, and pcDNA3-GST and the original pcDNA3–3HA were
generous gifts from Dr. H. Imataka. pESC-URA was purchased from
Stratagene, and the yeast two-hybrid vectors were described previ-
ously (13, 14). The yeast tandem affinity purification (TAP) tag strains
as well as diploid deletion strains in the BY4743 background and
haploid MAT strains in the BY4742 background were from Open
Biosystems. The yeast two-hybrid strains pJ69-4A and pJ69-4 as
well as the vectors pOAD and pOBD-2 were described previously
(13, 14).
To generate mammalian TAP tag vectors for the production of
N-terminal (NTAP) and C-terminal (CTAP) fusion proteins, the TAP
sequences (from the versions with two immunoglobulin binding do-
mains, a TEV site, and a calmodulin binding domain) from the Schiz-
osaccharomyces pombe vectors pREP-NTAP or pFA6a-2xPA-CTAP
(Ref. 15; kind gifts from Dr. K. Gould, Vanderbilt University) were
amplified by PCR. For NTAP, the 5 primer introduced a KpnI site,
whereas the 3 primer introduced sites for PmeI, AscI, PacI, and
BamHI. The PCR product was digested with KpnI and BamHI and
inserted into the KpnI and BamHI sites of pcDNA3 (Invitrogen). For
CTAP, the 5 primer added an XhoI site followed by sites for PmeI,
AscI, and PacI, whereas the 3 primer introduced an ApaI site. The
PCR product was digested with XhoI and ApaI and inserted into the
XhoI and ApaI sites of pcDNA3. Inserts were completely sequenced.
Unique sites and polylinker sequence for pcDNA3-NTAP and
pcDNA3-CTAP are shown in Supplemental Fig. 1 and at www.
proteomecenter.org.
To generate pcDNA3-flagnew and pcDNA3-EE (Glu-Glu), adapters
encoding the sequences MDYKDDDDKAAS and MEYMPMEAAS,
respectively, were cloned into the KpnI and PmeI sites of
pcDNA3-NTAP (thereby replacing the NTAP cassette with the appro-
priate epitope tag). pcDNA3–3HAnew was generated by amplifying
the triple HA tag from the original pcDNA3-3HA (a kind gift from
Dr. H. Imataka) and inserting this tag into the KpnI/PmeI sites of
pcDNA3-NTAP. All epitopes and multiple cloning site were
sequenced.
Coding sequences for proteins of interest were amplified by PCR
using Pfu Ultra from yeast genomic DNA (all yeast ORFs), a cDNA
library from HeLa cells (Stratagene; hTIP41, NM_152902; PP2AC,
NM_002715; PP2AC, NM_004156; PP4C, NM_002720; PP6C,
NM_002721), a cDNA library from human placenta (Ambion; PP4R2,
NM_174907), a pcDNA3-alpha4 (alpha4) construct kindly provided by
Dr. K. Arndt (NM_001551), or clones from the mammalian gene col-
lection (MGC) or IMAGE clones (KIAA2010, NM_032560; KIAA1387,
NM_020463; TCP1, NM_030752; PP1C, NM_002708). All accession
numbers in parentheses are from GenBankTM. Inserts were cloned
in-frame into appropriate vectors. 3 and 5 junctions of all inserts or
entire inserts obtained through library amplification were sequenced.
Preparation of Extracts and Detection of Expression Levels—For
stable cell pools, low passage number HEK293 cells (ATCC; CRL-
1573) were transfected with Lipofectamine PLUS (Invitrogen) accord-
ing to the manufacturer’s instructions and selected with 750 g/ml
active G418 (Mediatech cellgro). Selection medium was changed
every 2–3 days for 14 days when a stable cell population was
obtained. Expression was monitored, and cells were amplified further
to generate 10–20 150-mm plates per experiment.
Cells were washed three times in ice-cold PBS, harvested by
scraping, and then centrifuged to remove excess PBS. TAP lysis
buffer (10% glycerol, 50 mM Hepes-KOH, pH 8.0, 100 mM KCl, 2 mM
EDTA, 0.1% Nonidet P-40, 2 mM DTT, 10 mM NaF, 0.25 mM NaOVO3,
and 50 mM -glycerophosphate supplemented with 1 protease
inhibitor mixture (Sigma catalog number P8340), 5 nM okadaic acid,
and 5 nM calyculin A) was added (0.5–1 ml of lysis buffer/150-mm
plate), and the mixture was incubated on ice for 30 min. Lysis was
further enhanced by performing two freeze-thaw cycles. In prelimi-
nary experiments, varying concentrations of the specific serine/thre-
onine phosphatase inhibitors were used; the interactions reported
here were observed under all conditions.
Saccharomyces cerevisiae TAP tag strains (Open Biosystems) were
grown to OD 0.8–1.0 and harvested by centrifugation. After one
rinsing step in 20 mM Hepes, pH 7.5, 10 mM EDTA, cells were pelleted
and flash frozen. Pellets were thawed in TAP lysis buffer using 1 ml of
lysis buffer/g. Yeast were lysed by glass bead beating.
For the preparation of cleared extract from mammalian cells or
yeast, debris were pelleted via centrifugation (15,000 rpm for 30 min
at 4 °C), and protein concentration was determined by a Bradford-
type assay (Bio-Rad). Expression levels of recombinant proteins in
transfected mammalian cells or yeast strains were analyzed by sep-
arating 10–25 g of total cell extract by SDS-PAGE followed by
immunoblotting with normal rabbit serum (ICN Biomedicals Inc.;
1:2000) as the primary antibody and donkey anti-rabbit-horseradish
peroxidase (HRP) (Amersham Biosciences; 1:5000) as a secondary
antibody.
TAP Tag Purification—The purification strategy used here was
largely the same as that described by Rigaut et al. (16) with minor
modifications (see below) and adaptation for direct LC-MS analysis.
More details may be found at www.proteomecenter.org.
Mammalian cells or yeast were lysed in TAP lysis buffer, and
extracts were centrifuged to remove debris as described above.
Mammalian TAP tag purifications were performed with extract from
5–20 15-cm plates of stably transfected HEK293 cells (roughly 40–
150 mg of protein extract). Alternatively TAP purification was per-
formed with extract from 1–2 liters of yeast grown to OD 0.8–1.0.
Extracts were incubated with 100 l of packed, prewashed IgG-
Sepharose beads (Amersham Biosciences) for 4–6 h at 4 °C with
gentle agitation. Beads were pelleted and washed three times with
TAP lysis buffer and three times with TEV cleavage buffer (10 mM
Hepes-KOH, pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 0.5 mM
EDTA, and 1 mM DTT). Beads were then resuspended in 300 l of TEV
lysis buffer containing 100–200 units of recombinant AcTEV (Invitro-
gen) and returned to incubation with gentle agitation at 4 °C for 10–16
h. After TEV cleavage, the IgG beads were pelleted, and the super-
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natant was transferred to a fresh tube. IgG beads were rinsed three
times with calmodulin binding buffer (10 mM Hepes-KOH, pH 8.0, 150
mM NaCl, 10 mM -mercaptoethanol, 1 mM MgOAc, 1 mM imidazole,
0.1% Nonidet P-40, and 2 mM CaCl2), and all washes were combined
with the supernatant. CaCl2 (5 l of a 1 M stock) was added to the
mixture, which was centrifuged once more and then transferred to a
fresh tube containing 75 l of packed calmodulin-Sepharose beads
(Amersham Biosciences). Incubation was performed for 2–3 h at 4 °C
with agitation. The slurry was transferred into empty Bio-spin columns
(Bio-Rad), and the flow-through was removed through gentle air
pressure. Two washes in calmodulin binding buffer (750 l each) were
performed followed by three washes in calmodulin rinsing buffer (50
mM ammonium bicarbonate, pH 8.3, 75 mM NaCl, 1 mM MgOAc, 1 mM
imidazole, and 2 mM CaCl2). The last drops of rinsing buffer were
drained with gentle pressure, and Bio-spin columns were transferred
to fresh tubes. Two elutions with 100 l each of calmodulin elution
buffer (50 mM ammonium bicarbonate, pH 8.3, and 25 mM EGTA, pH
8.0) were performed, and the Bio-spin column was transferred into
another tube for two additional elutions.
Trypsin Digest and Preparation for Mass Spectrometry—Sequenc-
ing grade modified trypsin (Promega; 0.5–1 g) was added directly to
the eluate. Digestion was performed overnight at 37 °C. Following
digestion, the sample was lyophilized and then resuspended in re-
versed-phase HPLC buffer A (20 l; 0.4% AcOH, 0.005% heptaflu-
orobutyric anhydride in H2O). Prior to loading onto the reversed-
phase column, the sample was centrifuged at 13,000 rpm for 10 min,
and the supernatant was transferred to a fresh tube.
LC-MS/MS—Microcapillary reversed-phase columns (75-m inner
diameter, 363-m outer diameter; Polymicro Technology) were cut to
a final length of 15–20 cm, and spray tips were pulled in-house by
hand. Columns were packed in-house (12 cm) with Magic C18 100-Å,
5-m silica particles (Michrom, catalog number PM5/61100/00) using
a pressure bomb. Prior to loading the sample, columns were equili-
brated in HPLC buffer A. Half of the sample was applied to the column
using a pressure bomb and then washed off line in buffer A  5%
acetonitrile for 30–60 min. The LC column was then placed in front of
a Finnigan LCQmass spectrometer, programmed for data-dependent
MS/MS acquisition (one survey scan, three MS/MS of the most abun-
dant ions). After sequencing the same species three times, the
mass 3 Da was placed on an exclusion list for 3 min. Peptides were
eluted from the reversed-phase column using a multiphasic elution
gradient (5–14% acetonitrile over 5 min, 14–40% over 60 min, and
40–80% over 10 min). The remaining half of the sample was then
processed in the same manner. To prevent cross-contamination,
each sample was processed on a freshly prepared reversed-phase
column.
Data Analysis—Raw files generated by Xcalibur (Finnigan) were
converted to the mzXML format (17), and combined runs (from the
same sample) were searched using SEQUEST against the human
International Protein Index (IPI) database, version 3.01, or against the
Saccharomyces Genome Database (SGD) yeast ORF database (April
22, 2004 version). SEQUEST searches were performed without con-
straining for the number of tryptic termini, with a mass tolerance on
the precursor ion of 2, and methionine oxidation (16) as a variable
modification. SEQUEST html output was analyzed with INTERACT
(18), PeptideProphet (19), and ProteinProphet (20) using the default
parameters of each program. With the exception of Xcalibur and
SEQUEST, all other software tools are open source and available from
the Institute for Systems Biology (www.proteomecenter.org/software.
php).
Non-radioactive Transcription/Translation Assays—Mixtures of
plasmid DNA containing a T7 promoter (100–500 ng) were used to
program 25 l of a reticulocyte transcription/translation system con-
taining Transcend tRNA (Promega) essentially according to the man-
ufacturer’s instructions. Translated proteins were subjected to SDS-
PAGE and transferred to a nitrocellulose membrane. The membrane
was blocked for 1 h in PBS  0.5% Tween 20. Streptavidin-HRP
(Amersham Biosciences; 1:10,000) was used to detect the newly
synthesized proteins incorporating biotinylated lysine. After washing
the membrane (3 5 min with PBS 0.5% Tween 20; 3 5 min with
water), chemiluminescence was performed. Immunoprecipitations
were performed by diluting the TNT reaction with TAP lysis buffer and
incubating with 5–10 l of packed anti-HA beads (Roche Applied
Science) or anti-FLAG resin (Sigma). After three washes with TAP lysis
buffer, the sample was eluted directly in protein sample buffer lacking
reducing agent by incubation for 30 min at 37 °C. Reducing agent was
added, and the sample was boiled and loaded onto SDS-PAGE gels.
Cisplatin Sensitivity Assay in Drosophila—flfl2 (I57T) and flfl3 (pre-
mature stop codon at position 347) are ethyl methanesulfonate-in-
duced alleles. Healthy heterozygous flies carrying either flfl2 or flfl3
over a marker chromosome (MKRS) were maintained on apple agar
plates at 25 °C and allowed to lay eggs for 24 h. Agar plates were then
changed and incubated for another 24 h at 25 °C. First instar larvae
were collected and distributed to vials containing standard fly food
into which the cisplatin solution was allowed to diffuse. Cisplatin
powder (Alexis Biochemicals, Lausanne, Switzerland) was dissolved
in 0.9% NaCl to obtain 0.4, 0.8, and 1.2 mM stock solutions. To test
for putative undesirable effects of the MKRS marker chromosome,
MKRS/ flies were also tested for cisplatin sensitivity. The MKRS/
as well as the control flfl2/ or flfl3/ flies showed no change in
cisplatin sensitivity as compared with wild type flies.
RESULTS
Identification of Human PP4C-binding Proteins—TAP tag-
ging and mass spectrometry, in which a protein complex of
interest is purified in a two-step affinity enrichment process
and its components are identified by the fragment ion spectra
of selected tryptic peptides, have proven to be invaluable
tools in the characterization of protein complexes (16, 21–23).
As compared with single tag purification strategies, samples
isolated by TAP tagging are significantly cleaner, thereby
reducing the likelihood of false-positive identifications. Harsh
washing conditions are also not necessary, allowing for re-
covery of native complexes. Another advantage of such ap-
proaches is that they are generic, making them particularly
suited to the study of interaction networks in which binding
partners for multiple proteins can be analyzed in parallel.
To gain insight into the supramolecular architecture of PP4-
containing complexes, we tagged the catalytic subunit at its N
terminus with a TAP tag, expressed this protein stably in
HEK293 cells, and then processed the tagged protein along
with its binding partners for purification (see “Experimental
Procedures” and Fig. 1A). Eluted proteins were subjected to
LC-MS/MS and identified via database searching followed by
statistical analysis of the search results using a suite of soft-
ware tools, including PeptideProphet and ProteinProphet
(Refs. 19 and 20; see “Experimental Procedures”). To estab-
lish a list of background contaminant proteins, we analyzed
cells stably expressing the TAP tag alone. In addition, proteins
detected in numerous unrelated samples were flagged as
dubious interactors and added to the contaminant list (see
Supplemental Table I). For a list of PP4C-interacting pro-
A PP4 Complex Involved in Cisplatin Sensitivity
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teins see Table I. The data are also represented pictorially in
Fig. 1B.
In addition to the recovery of the TAP-tagged “bait” protein
itself (PP4C), we observed a number of peptides derived from
the known PP4C regulatory subunits PP4R1 and PP4R2 (Ta-
ble I). We also observed many peptides derived from alpha4
(IGBP1) previously demonstrated to interact directly with all of
the PP2A-like phosphatase catalytic subunits (24, 25). Alpha4
is the ortholog of the yeast Tap42 protein, which links the target
of rapamycin signaling pathway to PP2A-type phosphatases
(26–28). However, the role of the PP2A-type phosphatases
in rapamycin-sensitive signaling in mammals is not well
understood.
Interestingly our analysis also identified all eight subunits of
FIG. 1. Protein-protein interactions surrounding the mammalian PP4 catalytic subunit and identification of novel PP4C-interacting
partners. A, iterative TAP tag strategy to detect interacting proteins. B, proteins present in the TAP tag purification of the PP4 catalytic subunit.
Only interactions detected in our TAP tag experiments are represented. Green arrows represent interactions that were also previously reported,
whereas red arrows indicate novel interactions. C, PP4R3 is conserved throughout eukaryotic evolution. Shown is the alignment between
KIAA2010, KIAA1387, Falafel, and Psy2p. Green boxes represent armadillo (ARM)/HEAT repeats, and the yellow box indicates a domain with
homology to the Ran binding domain of RanBP1 as well as moderate homology with pleckstrin homology (PH) and EVH1 domains. D, PP4C
interaction network. Arrows indicate directionality; bait 3 prey. hTIP41 and alpha4 were also found to be associated with the PP2A and PP6
phosphatases. E, PP4C appears to be a component of several different types of mutually exclusive complexes.
TABLE I
Human protein interactions detected by mass spectrometry
A PP4 Complex Involved in Cisplatin Sensitivity
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an ATP-dependent chaperonin, the TRiC/CCT complex. The
TRiC/CCT complex was initially thought to be highly special-
ized for the folding and assembly of actin and tubulin, but
recent work suggests that it participates in the folding and
assembly of a broader range of substrates (23). The interac-
tion with TRiC/CCT appears to be evolutionarily conserved as
both Pph3 (the ortholog of PP4C) and Tap42 also co-precip-
itated with this complex in a large scale study (29). The
functional significance of the TRiC/CCT complex interaction
with PP4cat is unknown at this time.
A Novel Evolutionarily Conserved Protein Interacts with
PP4C—Other than the known PP4C-interacting partners and
the TRiC/CCT complex, only two additional (non-contami-
nant) proteins were detected in the TAP-PP4C purification:
KIAA2010 and KIAA1387. The human KIAA2010 is 820 aa in
length, and KIAA1387 is 764 aa. The two proteins share 67%
sequence identity and 77% homology at the amino acid level
(Fig. 1C). To be consistent with the nomenclature of the
PP2A-type phosphatases, here we refer to KIAA2010 as
PP4R3 and to KIAA1387 as PP4R3 (see below for further
justification). PP4R3-like proteins are conserved throughout
Eukaryotae: the Drosophila falafel (flfl) protein shares 58%
identity with KIAA2010 at the amino acid level, and the S.
cerevisiae Psy2 protein exhibits 27% identity with KIAA2010
over 699 amino acids (Fig. 1C).
The predicted two- and three-dimensional structure of the
PP4R3 protein family indicates that a 115-aa fragment at the
extreme N terminus shares extensive structural homology
with a Ran binding domain found in RanBP1 (Fig. 1C). The
predicted structure of this fragment is also reminiscent of
pleckstrin homology domains. The Ran binding-like region is
the most conserved portion of the protein across species,
sharing 46% identity (60% similarity) at the amino acid level
with yeast Psy2p and 87% identity (95% similarity) with flfl.
Threading algorithms (30) indicate that the KIAA2010 and
KIAA1387 proteins also possess a number of HEAT or arma-
dillo repeats. Whether PP4R3 can interact with Ran is un-
known at this time; we were unable to detect this interaction
by co-immunoprecipitation following in vitro translation or
co-transfection in 293 cells (data not shown).
Interestingly small interfering RNAs directed against
KIAA1387 shorten mitotic transit time (31). Falafel (flfl) was
first identified in a modular misexpression screen designed to
identify novel dRac-specific signaling components; loss of flfl
resulted in defects in dorsal closure, a phenomenon also
associated with dRac deletion (Ref. 32; see below). Finally the
yeast PP4R3 homolog was dubbed Psy2p based on hyper-
sensitivity of deletants to the anticancer drug cisplatin (Ref.
10; see below).
Mammalian PP4 Module Interaction Network—To confirm
the observed novel interactions and to better understand the
supramolecular architecture of PP4C-containing complexes
in mammals, we cloned the human alpha4, PP4R1 (PPP4R1),
PP4R2 (PPP4R2), and PP4R3 (KIAA2010) ORFs into TAP tag
vectors, established HEK293 cell lines stably expressing
these tagged proteins, and repeated the purification and
mass spectrometric identification process for each of these
proteins and their interacting partners (Fig. 1, A and D, and
Table I).
The PP4R1 pull-down yielded only the bait itself and PP4C.
No peptides derived from alpha4, the TRiC/CCT complex,
PP4reg2, or PP4reg3 were detected in these experiments
(Table I). Alpha4 pull-downs yielded primarily TRiC/CCT com-
plex proteins in addition to a single PP4C peptide and a few
peptides from the other known alpha4 binding partners
(PP6C, one peptide; and PP2AC, three peptides). In a PP4R2
pull-down, the TAP-tagged protein itself and PP4C were iden-
tified as well as many peptides from PP4R3 and PP4R3.
Thus, as with PP4C, PP4R2 appeared to be present in a
complex with PP4R3 and/or PP4R3. In addition to these
proteins, the PP4R2 pull-down also yielded MGC3794, the
human homolog of S. cerevisiae Tip41 (Tap42-interacting pro-
tein, molecular mass of 42 kDa), a protein involved in rapa-
mycin signaling through phosphatase regulation (33, 34). We
cloned the MGC3794 ORF (hereafter referred to as hTIP41)
into the TAP tag vectors and repeated the pull-down/identifi-
cation process with this fusion protein. PP4C and PP4R2
peptides (in addition to other phosphatase subunits, which
will be reported elsewhere) were identified. This observation is
intriguing because the yeast Tip41 protein was reported to
interact with the yeast alpha4 homolog Tap42 and to prevent
Tap42 from forming complexes with phosphatases (Ref. 33;
see “Discussion”). Finally a pull-down of PP4R3 (KIAA2010)
confirmed the interaction with PP4C and PP4R2. No addi-
tional proteins were identified in the PP4R3 pull-down.
Taken together, these data suggest that PP4C is present in
several distinct complexes: 1) a binary complex with PP4R1,
2) a complex involving alpha4 and the chaperonin TRiC/CCT,
FIG. 2. Assembly and specificity of the PP4CPP4R2PP4R3 complex. A and B, epitope-tagged versions of PP4R3 (EE tag), PP4R2 (3HA
tag), and PP4C (FLAG tag) were co-translated in a reticulocyte lysate containing biotinylated lysine ( denotes addition of the corresponding
cDNA to the reaction). Following co-translation, reactions were either analyzed directly by SDS-PAGE (bottom panels) or incubated with an
anti-FLAG Sepharose resin (A) or anti-HA Sepharose resin (B) prior to gel analysis. Proteins were transferred to nitrocellulose and visualized
by incubation with streptavidin-HRP followed by chemiluminescence. Black dots denote the location of the weaker PP4C band. C, model
depicting the preassembly of a binary complex between PP4C and PP4R2 prior to the stable association of PP4R3 into PP4cs. D and E,
specific interactions of PP4R2 and PP4R3 (but not hTIP41) with PP4C. PP4R2 (3HA-tagged; D), PP4R2  PP4R3 (EE-tagged; D), or hTIP41
(GST-tagged; E) were co-translated in a reticulocyte lysate with the indicated FLAG-tagged catalytic subunit. Following translation, samples
were analyzed directly via SDS-PAGE (bottom panels) or immunoprecipitated as above using an anti-FLAG Sepharose resin (top panels). IP,
immunoprecipitation.
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and 3) a complex containing PP4R2 and PP4R3, which may
also include hTIP41 (Fig. 1E). The PP4CPP4R2PP4R3 complex
will be referred to throughout this study as PP4cs (see below).
These results also demonstrate how an iterative TAP tagging/
mass spectrometry approach may be used to characterize the
components of individual multiprotein complexes.
Interaction of PP4R3 with PP4C Requires Preassembly of
PP4C and PP4R2—We next confirmed that PP4C, PP4R2,
and PP4R3 (KIAA2010) form a multimeric complex. Each
protein was tagged at its N terminus with a different epitope
tag to allow for detection and immunoprecipitation. Plasmid
DNA coding for each of the tagged proteins was used to
program a coupled transcription/translation (TNT) reticulocyte
lysate containing biotinylated lysine (see “Experimental Pro-
cedures”). Following separation by SDS-PAGE and transfer to
a nitrocellulose membrane, translation products were de-
tected using streptavidin conjugated to HRP. When all three
proteins were co-translated, both 3HA-tagged PP4R2 and
Glu-Glu (EE)-tagged PP4R3 were co-immunoprecipitated
with FLAG-tagged PP4C (Fig. 2A, lane 6). (The 3HA-PP4R2
constructs often yielded two products with slightly different
electrophoretic mobilities. This is most likely because of al-
ternative translation initiation start site usage, since the
smaller product does not react with the anti-HA antibody.)
Similarly a 3HA-PP4R2 protein pull-down (Fig. 2B, lane 5)
co-precipitated both FLAG-PP4C and EE-PP4R3. Exclusion
of PP4R3 from the TNT reaction had no apparent effect on the
interaction between FLAG-PP4C and 3HA-PP4R2 (Fig. 2A,
lane 5). Thus, binary complex formation between FLAG-PP4C
and 3HA-PP4R2 is not dependent on PP4R3. Importantly,
however, omission of 3HA-PP4R2 from the TNT mixture pre-
cluded co-immunoprecipitation of EE-PP4R3 with FLAG-
PP4C (Fig. 2A, lane 4), suggesting that PP4R2 is necessary to
mediate the interaction between PP4C and PP4R3. Consist-
ent with this observation, a two-hybrid association between
the putative yeast orthologs of PP4R2 (Ybl046w) and PP4R3
(Psy2p; Ynl201c) was reported previously in a large scale
study (Ref. 35; also see below). However, a putative direct
interaction between PP4R2 and PP4R3 in the TNT system is
apparently not sufficient for the formation of a stable complex
as omission of FLAG-PP4C from the TNT mixture prevented
efficient co-precipitation of EE-PP4R3 with 3HA-PP4R2 (Fig.
2B, compare lanes 4 and 5). It thus appears that a binary
complex between PP4C and PP4R2 must be assembled be-
fore PP4R3 can stably interact as illustrated in Fig. 2C. This
situation differs from the assembly of PP2AC-containing tri-
meric complexes in that the adapter (A subunit, or PPP2R1)
can efficiently co-precipitate either the catalytic or the regu-
latory B subunits (e.g. Ref. 36).
PP4R2 and PP4R3 Interact with PP4C but Not with the
Related Phosphatases PP2AC or PP6C—Our TAP tagging
data strongly suggested that the binding of PP4R3 and
PP4R2 is specific to PP4C: no peptides derived from other
phosphatases were recovered following TAP-mediated puri-
fication of PP4R2 or PP4R3. Similarly no PP4R2 or PP4R3
(KIAA2010 or KIAA1387) peptides were observed following
TAP-mediated purification of PP2AC, PP6C, or PP1C (data
not shown). To confirm these observations, we tested
whether the two regulatory proteins can co-precipitate with
the other mammalian PP2A-type phosphatases. The coding
sequences for PP2AC (PPP2CA), PP2AC (PPP2CB), and
PP6C (PPP6C) were cloned into the pcDNA3-flag vector and
co-translated in a TNT lysate with 3HA-PP4R2 alone (Fig. 2D,
lanes 1–4) or 3HA-PP4R2 and EE-PP4R3 (lanes 5–8). All cata-
lytic subunits were expressed (bottom panel), yet PP4R2 and
PP4R3 were only co-precipitated on an anti-FLAG Sepharose
resin when co-expressed with FLAG-PP4C (lanes 3 and 7). The
interaction with PP4C is thus specific, and PP4R3 (KIAA2010)
appears to be a bona fide PP4 regulatory subunit.
The specificity of the PP4cs intracomplex interactions con-
trasts with that of hTIP41, which interacted with all of the
PP2A-like phosphatase catalytic subunits in our study. Con-
sistent with this, GST-hTIP41 co-translated with the FLAG-
tagged phosphatases in the TNT system was efficiently co-
immunoprecipitated with FLAG-PP2AC, FLAG-PP4C, and
FLAG-PP6C (Fig. 2E, lanes 2–4). However, the serine/threo-
nine phosphatase PP1C (the PPP phosphatase most closely
related to PP2A with 41% identity to PP2AC) was unable to
precipitate hTIP41 (lane 1). In this respect, hTIP41 resembles
the human alpha4 protein, which can establish interactions
with all PP2A-type phosphatases (24). In contrast to a previ-
ous report documenting an interaction between the S. cerevi-
siae Tip41 and Tap42 proteins (33), hTIP41 was unable to
co-precipitate FLAG-alpha4 (Fig. 2E, lane 5). Taken together,
these results indicate that hTIP41 can interact with all of the
PP2A-type phosphatase catalytic subunits and is therefore
not a specific interacting partner for the PP4 complex.
Interaction among Yeast Orthologs of the PP4 Complex—
The S. cerevisiae genome contains orthologs of the mamma-
lian PP4C, PP4R2, and PP4R3 proteins. The protein sharing
the most homology to PP4R3 in S. cerevisiae is Psy2
(Ynl201c; Fig. 1C). The yeast Pph3 protein (Ydr075w) is most
closely related to PP4C, although the sequences of the other
S. cerevisiae PP2A-type phosphatases (Sit4, Pph21, Pph22,
and Ppg1) are also closely related. Although no yeast protein
exhibits sequence homology to PP4R2 throughout its entire
sequence, the Ybl046w ORF possesses a small stretch of
homology in its N terminus. Large scale experiments have
provided evidence for interactions between these yeast or-
thologs; a two-hybrid interaction was reported between Psy2
and Ybl046w (35), and complexes containing Pph3, Ybl046w,
and Psy2 (along with other proteins) have been detected
using pull-down/mass spectrometry approaches (29, 37). We
thus set out to determine whether yeast Pph3-containing
complexes were organized in a manner similar to mammalian
PP4C-containing complexes and whether a PP4cs-like com-
plex has been conserved throughout evolution. To this end,
we obtained yeast strains expressing C-terminally TAP-
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tagged Pph3, Ybl046w, Psy2, and Tip41 proteins and used
the same purification and mass spectrometry approach to
identify interacting partners for these polypeptides. As shown
in Table II and Fig. 3, interactions among the yeast proteins
were extremely similar to those we observed for the human
PP4cs proteins: Pph3, Ybl046w, and Psy2 all established
reciprocal interactions. As in the mammalian system, Tip41p
was also associated with this complex, although the coverage
ratio suggests that it was present in lower amounts than the
other components. We did not detect the TRiC/CCT complex
or alpha4 in the Pph3-TAP pull-down; however, this may be
due to the presence of the relatively large TAP tag at the C
terminus of the protein (the mammalian PP4C was tagged at
its N terminus) as both Pph3-FLAG and Tap42-FLAG were
previously shown to co-precipitate with the TRiC/CCT com-
plex (29).
Interestingly, we also detected the transcription elongation
factor complex components Spt4 and Spt5 in TAP tag puri-
fications of both Psy2 and Ybl046w (Spt5 was also detected
previously as a Psy2 and Ybl046w interactor in a large scale
experiment; Ref. 37). Conversely purification of TAP-tagged
Spt5 yielded Spt4 and RNA Pol II subunits, as expected, in
addition to several peptides for Psy2, Ybl046w, and Pph3. A
putative role for PP4cs may thus be to target the Pph3 phos-
phatase to the transcription elongation machinery.
The Yeast PP4cs Complex Is Involved in the Response to
Cisplatin-induced DNA Damage—A genome-wide scan for
hypersensitivity to the DNA-damaging agents cisplatin and
oxaliplatin (10) yielded three novel uncharacterized genes,
including platinum sensitivity 2 (PSY2; YNL201c; Ref. 10).
Interestingly PPH3 deletion was also found to render cells
hypersensitive to cisplatin treatment (10). Deletion of PPH3 or
PSY2 was also reported to moderately increase the sensitivity
of S. cerevisiae to methyl methanesulfonate (38). Because in
mammalian cells PP4R2 is an obligatory partner for the asso-
ciation of PP4C and PP4R3, and Tip41 associates with PP4cs
in yeast and mammals, we characterized the sensitivity of
yeast lacking the YBL046W or TIP41 (YPR040W) genes to
cisplatin treatment. Diploid yeast strains were treated with
cisplatin or vehicle alone, and the growth of yeast was mon-
itored 36 h after plating onto fresh YPD agar plates. As ex-
pected from the large scale studies, deletion of PPH3, PSY2,
or the polymerase -associated protein REV1, rendered cells
hypersensitive to cisplatin treatment (Fig. 3C). Importantly,
and consistent with a role for the entire yeast PP4cs complex
in cisplatin sensitivity, deletion of YBL046W also elicited cis-
platin hypersensitivity. Interestingly, deletion of TIP41 yielded
an intermediate phenotype, exhibiting more sensitivity than a
wild type strain yet less sensitivity than the PSY2, PPH3, or
YBL046W deletants. Strains deleted for the PPH3-related
PPH22 or PPZ2 phosphatases displayed cisplatin sensitivity
similar to the parental strain in this screen. To control for
spurious results due to secondary mutations, we repeated the
experiment with a haploid deletion set and obtained identical
results (Fig. 3D). Thus, the yeast PP4 complex containing
Pph3, Ybl046w, and Psy2 plays a crucial role in viability
following cisplatin-induced DNA damage. Tip41 may play a
role as a modulator or facilitator perhaps by making the PP4
complex more available to substrate(s) following DNA dam-
age treatment.
Because Psy2, Pph3, and Ybl046w interacted with Spt4
and Spt5 in the TAP tag pull-down experiments and Spt4 was
implicated in the shutdown of Pol II-mediated transcription
following DNA damage (possibly via dephosphorylation of Pol
II Ser-5; Ref. 39), we reasoned that the involvement of the
PP4cs proteins in cisplatin resistance may be effected
TABLE II
Yeast protein interactions detected by mass spectrometry
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FIG. 3. Comparison of yeast and human PP4C interaction maps and cisplatin sensitivity of individual yeast deletion strains. A and B,
schematic organization of the multiprotein complexes recovered and identified by TAP tagging and mass spectrometry. Human data are also
shown in Fig. 1 and Table I; yeast data are extracted from Table II. Arrows denote directionality of the interaction (bait 3 prey) and are
color-coded as in Fig. 1. Colored nodes represent proteins used as bait in the TAP tagging procedure, whereas gray nodes represent proteins
that were not analyzed further. The beige diamond encompasses the PP4CPP4R2PP4R3hTip41 complex conserved from yeast to mammals.
C and D, cisplatin sensitivity of yeast strains harboring deletions for PP4cs complex components. Diploid (C) or haploid (D) S. cerevisiae
A PP4 Complex Involved in Cisplatin Sensitivity
1734 Molecular & Cellular Proteomics 4.11
 at SM
AC Consortium
 - Zurich on Septem










through SPT4 and SPT5. Therefore, homozygous diploid
SPT5 deletant and haploid SPT4 and SPT5 deletion strains
were tested for cisplatin sensitivity. In the absence of cispla-
tin, both strains grew slightly slower than the parental strain.
However, none of the SPT4/5 strains exhibited significant
hypersensitization to cisplatin (Fig. 3, C and D). Thus, SPT4
and SPT5 are not likely to be key mediators of the cisplatin
sensitivity caused by PP4cs deletion.
Psy2 Interacts with Rad53—In an attempt to elucidate how
PP4cs and Tip41 are connected to the DNA damage repair
machinery, we turned to a yeast two-hybrid strategy. Psy2
was previously reported to interact with Rad53 in the yeast
two-hybrid assay (Rad53 was used as bait; Ref. 13). We
attempted to verify this interaction using the reverse config-
uration with Rad53 cloned into a prey vector and Psy2 ex-
pressed from a bait vector. In addition, we tested pairwise
interactions among all of the components of our yeast PP4
complex and explored putative interactions with other com-
ponents of the DNA damage machinery. A total of 31 non-
redundant prey-containing yeast strains were mated in dupli-
cate to strains expressing Psy2, Ybl046w, Pph3, Tip41, and
Rad53 from the bait vector. Although a previous study utilized
Rad53 as bait, our own bait strains harboring Rad53 mated
inefficiently, and two-hybrid interactions could not be tested
for this strain. The other bait strains were tested in a 96-well
format, and the growth of colonies on media lacking histidine
was monitored. By plating the yeast on selection media con-
taining varying amounts of 3-aminotriazole (a stoichiometric
inhibitor of His3p activity), background levels could be effi-
ciently controlled such that growth of negative controls (e.g.
vector alone) served as a base line to score positives. As
previously reported, bidirectional interactions were detected
between Psy2 and Ybl046w (Fig. 4, A and B). In addition,
Tip41 (bait) interacted with Pph3 (prey), Pph21, Pph22 (Fig.
4A), Sit4, and Ppg1 (not shown). We also detected a previ-
ously unreported bidirectional interaction between Pph3 and
Ybl046w. Consistent with our TAP tag data, Psy2 strongly
interacted with Spt4 and Spt5 in the two-hybrid assay. Finally
a strong signal was also observed between Psy2 (bait) and
Rad53 (prey). No signal was detected for Rad53 with any of
the other baits tested. Additionally no signal was detected
between any of the baits tested and strains containing prey
vectors expressing other proteins involved in DNA damage
(not shown). These data suggest that the yeast PP4cs com-
plex is connected to the DNA damage machinery via an
interaction between Psy2 (PP4R3) and Rad53.
PP4R3 Is a Functional Homolog of Psy2—To determine
whether the yeast and human PP4cs are functionally equiva-
lent in the cisplatin sensitivity assay, we reintroduced a FLAG-
tagged galactose-inducible Psy2 or mammalian PP4R3 (or
vector alone) into the psy2 diploid strain. We then performed
cisplatin sensitivity assays as above. As expected, the psy2
strain (transformed with vector alone) was much more sensi-
tive to cisplatin treatment than the parental strain (trans-
formed with vector alone; Fig. 5A), although the magnitude of
this effect was less pronounced on the synthetic defined
media used for this assay than on YPD media as used in Fig.
4. psy2 strains transformed with FLAG-Psy2 (two independ-
ent transformants tested) exhibited a level of cisplatin sensi-
tivity similar to the parental strain (Fig. 5A). Strikingly expres-
sion of FLAG-tagged mammalian PP4R3 also reverted the
cisplatin hypersensitivity of a psy2 strain, indicating that
Psy2 and PP4R3 are functionally equivalent in mediating re-
sistance to cisplatin.
To determine whether human PP4R3 can establish the
same two-hybrid contacts with the yeast prey proteins as
Psy2, we mated a yeast bait strain expressing human PP4R3
to our prey array. Although we did not detect interactions with
Ybl046w, Spt4, or Spt5, PP4R3 strongly interacted with yeast
Rad53 (this was, in fact, the only interaction we detected; Fig.
5B). It thus appears that an interaction between PP4R3/Psy2
and the DNA damage machinery has been evolutionarily
conserved.
Cisplatin Hypersensitivity of PP4R3 Mutants in Higher Eu-
karyotes—To investigate whether a reduction in PP4R3 activ-
ity renders a multicellular organism hypersensitive to cisplatin,
we assayed animals harboring mutations in the Drosophila
falafel (flfl) gene, which encodes the fly homolog of the
PP4R3/Psy2 protein (Fig. 1C). Two ethyl methanesulfonate-
induced mutant alleles, flfl2 and flfl3 (see “Experimental Pro-
cedures”), were identified in a reversion assay for an enhancer
and promoter-mediated flfl gain-of-function phenotype.2 Al-
though flies homozygous for either mutation (flfl2/flfl2 or flfl3/
flfl3) were inviable, 30% of animals possessing the heteroal-
lelic combination flfl2/flfl3 reached adulthood and displayed a
statistically significant reduction in size as compared with
their wild type counterparts (weight reduction of 23% in
females and 12% in males).
Mutant first instar flfl2/flfl3 larvae were placed onto standard
fly food supplemented with increasing concentrations of cis-
platin (see “Experimental Procedures”), and emerging adult
flies were counted 3 days after eclosion. (The survival of
mutant flfl2/flfl3 animals is compromised even in the absence
of cisplatin, so these data were normalized to the survival of
flfl mutants in the absence of the drug.) Survival curves for
flfl2/flfl3 mutants and control animals grown on increasing
2 M. Zarske and E. Hafen, manuscript in preparation.
deletion mutants were grown to OD  0.4 and then treated with 1 mM cisplatin (or DMSO vehicle alone) for 4 h. Serial 10-fold dilutions were
plated onto YPD, and growth was monitored 36 h post-treatment. Pph22 is a yeast homolog of the PP2A catalytic subunit, whereas Ppz2 is
a homolog of the human PP1 catalytic subunit. rev1 was used here as a positive control.
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FIG. 4. Psy2p interacts with Rad53p. Coding sequences for Psy2p, Ybl046w, Pph3p, and Tip41p were cloned into the yeast two-hybrid bait
vector pOBD-2, and the constructs were transfected into the pJ69-4a strain. A miniarray of “prey” in pOAD/pJ69-4, extracted from a larger
collection described previously (13), was supplemented with a collection of cDNAs coding for Psy2, Ybl046w, Pph3, Tip41, and Rad53 in
pOAD/pJ69-4 and generated in parallel to the bait. The final prey array consisted of the following proteins: Spt4, Rad6, Rev7, Mrc1, Ybl046w,
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concentrations of cisplatin are shown in Fig. 5C. Female flfl2/
flfl3 mutant flies displayed reduced survival at 0.4 M cisplatin
compared with wild type flies (Fig. 5C). No flfl2/flfl3 individuals
survived when exposed to 0.8 or 1.2 M cisplatin, whereas
some wild type animals emerged (identical results were ob-
served with male flfl mutant animals; data not shown). These
results suggest that falafel (PP4reg3) function in higher eu-
karyotes is required for resistance to cisplatin treatment and
provide further evidence for a critical and evolutionarily con-
served role of this PP4C-interacting partner in the response to
DNA damage.
DISCUSSION
Here, using an iterative TAP tagging/mass spectrometry
approach, we report that the mammalian PP4 catalytic sub-
unit is a component of several different mutually exclusive
subcomplexes: one containing PP4R1, another containing
alpha4 and the TRiC/CCT complex, and a third (PP4cs) con-
taining PP4R2 and a novel protein that we termed PP4R3. The
PP4cs complex is evolutionarily conserved and in yeast is
composed of the Pph3, Ybl046w, and Psy2 proteins. The
conservation in S. cerevisiae suggested a role for PP4cs in
resistance to cytotoxic agents: genome-wide screens of the
yeast deletion collection with the DNA-damaging agents cis-
platin, oxaliplatin, mitomycin C, and methyl methanesulfate
have highlighted the importance of both PPH3 and PSY2 in
survival following exposure to these agents (10, 38). We dem-
onstrated that yeast strains deleted for YBL046W (PP4R2) are
hypersensitive to cisplatin to the same extent as strains de-
leted for either PPH3 or PSY2. The mammalian ortholog of
Psy2, PP4R3, could substitute for the yeast protein in cisplatin
sensitivity assays, suggesting that the mammalian complex
plays a similar role. Furthermore in Drosophila, mutation of the
falafel gene, the ortholog of Psy2, led to increased cisplatin
sensitivity.
How might the PP4CPP4R2PP4R3 complex be linked to
the DNA damage response? A previous yeast two-hybrid
screen for Rad53-interacting partners yielded Psy2 (13). We
confirmed this observation and demonstrated that the inter-
action is independent of Rad53 kinase activity (data not
shown). Rad53 (or CHK2 in humans) is a critical component in
a DNA damage checkpoint response conserved from yeast to
humans (human ortholog CHK2; Refs. 40 and 41). We were
not able to detect Rad53-Psy2 or human CHK2-PP4R3 inter-
actions by pull-down assay, suggesting that these interac-
tions are transient or easily disrupted through our purification
protocol or that the interactions may be substoichiometric.
Rad18, Rrd1, Rad10, Rad2, Pho85, Ppg1, Luc7, Pph3, Rrd2, Tip41, Pph22, Pph21, Ynr069c, Ahc1, Hol1, Psy2, Rad53, Rev1, Rad1, Spt5,
Rad26, Rad9, Rev3, Mec1, Sit4, and Mrp144. Bait and prey strains were mated, and growth on selective medium (lacking histidine and
containing various amounts of 3-aminotriazole) was monitored. A, representative results for each mating. Positive results are framed in red. B,
summary of the interactions detected by the yeast two-hybrid method in this and other studies. Proteins used as bait are denoted by colored
nodes. Red arrows indicate novel interactions reported for the first time in this study; green arrows indicate interactions detected in this study
as in previous reports; and the blue arrow represents an interaction reported in the literature but not tested here.
FIG. 5. PP4R3 from higher eukaryotes is involved in cisplatin
sensitivity. A, mammalian PP4R3 functionally replaces PSY2 in the
cisplatin sensitivity assay. Yeast Psy2 or mammalian PP4R3 cDNAs
were cloned into the galactose-inducible pESC-ura vector and trans-
formed into the diploid yeast strain lacking PSY2. Individual clones
were selected. Expression of the recombinant cDNAs was driven
through growth on galactose for 8 h prior to cisplatin treatment (4 h).
A serial 10-fold dilution series was plated onto minimal medium
lacking uracil but containing galactose to maintain expression.
Growth was monitored 48 h post-treatment. B, mammalian PP4R3
interacts with yeast Rad53. A yeast two-hybrid assay using human
PP4R3 as bait was performed as in Fig. 5 in duplicate. C, flies lacking
functional PP4R3 (flfl) are hypersensitive to cisplatin. Survival of flfl
heterozygous (control, MKRS/flfl2, or MKRS/flfl3) and flfl2/flfl3 het-
eroallelic mutant female flies following cisplatin treatment. Numbers
of surviving flies at various concentrations of cisplatin were normal-
ized to the numbers of untreated animals. Similar results were ob-
tained with male flies. Experiments were performed in triplicate at all
concentrations with 100 flies per concentration.
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Other links between PP4cs and DNA damage also exist.
Yeast PP4cs associates with Spt4 and Spt5, transcription
elongation factor proteins linked to DNA damage-induced Pol
II dephosphorylation at Ser-5, and subsequent transcriptional
shutdown (39). However, deletion of Spt4 or Spt5 did not
result in hypersensitivity to cisplatin, indicating that the
PP4cs-Spt4-Spt5 interaction is not sufficient to explain the
cisplatin sensitivity phenotype.
Psy2 was also reported previously to genetically and phys-
ically interact with Wss1 and Tof1, two proteins presumed to
play a role in the stabilization of stalled replication forks (42).
In human cells, additional links between PP4C and/or the
PP4cs complex and cisplatin-induced DNA damage may
exist. For instance, cisplatin-induced NF-B activation ap-
pears to be mediated, at least in part, by PP4C-mediated
dephosphorylation of NF-B p65 at Thr-435 (43). The pre-
cise contribution of each of these pathways to the cisplatin
hypersensitivity phenotype of the PP4cs deletants remains
to be assessed.
Cisplatin and related platinum compounds such as carbo-
platin are effective against many types of solid tumors, includ-
ing cervical, ovarian, head-and-neck, and non-small cell lung
cancers (for a review, see Ref. 44). Cisplatin analogs have also
proven particularly effective against testicular cancer for
which the overall cure rate exceeds 90% (for a review, see
Ref. 12). However, intrinsic or acquired resistance to cisplatin
analogs is frequently encountered, significantly limiting the
application of this class of drugs (12). Resistance may be
attributed to several factors, including decreased drug accu-
mulation, increased cellular detoxification, enhanced DNA re-
pair, tolerance to platinum-induced DNA damage, and alter-
ations in signal transduction pathways (11). Cisplatin
resistance is thus a major hurdle in cancer therapies, and a
primary goal in designing new platinum-based anticancer
agents has been to circumvent this problem (45).
The sensitization to cisplatin of S. cerevisiae deleted for any
of the PP4cs members suggests that inactivation of the hu-
man PP4cs components during cisplatin treatment may sen-
sitize cisplatin-resistant tumor cells to the drug. In support of
this possibility, two different cell lines selected for cisplatin
resistance through long term cisplatin treatment demon-
strated a striking reversal to a sensitive phenotype when
co-treated with low doses of demethylcantharidin or okadaic
acid, two PP2A inhibitors (46, 47). PP4C is also sensitive to
these compounds (48) and was likely inhibited in these stud-
ies. Novel platinum-based compounds comprised of two moi-
eties, the platinum group and demethylcantharidin, elicited
sensitivity of these cisplatin-resistant cell lines only when the
compounds exhibited activity toward PP2A (46, 47). Based on
the shared sensitivity of PP2AC and PP4C to cantharidin-
based compounds, PP4C is also likely targeted by these
compounds. A drug that targets the assembly of PP4cs,
perhaps by preventing PP4R2 from binding to PP4C or
PP4R3, could thus potentially synergize with cisplatin while
having fewer side effects than drugs inhibiting all PP2A-type
subunits.
Finally a different type of anticancer compound, rapamycin,
was also demonstrated to enhance cisplatin sensitivity in cell
and animal models (e.g. Ref. 49). Rapamycin actions are
conserved from yeast to humans and appear to involve mod-
ulation of PP2A-type phosphatase activity through Tap42 (al-
pha4) and Tip41 (at least in yeast). Rapamycin analogs are
used in the clinic to prevent graft rejection and as anticancer
agents (for reviews, see Refs. 50 and 51). Recently the syn-
ergy between cisplatin and rapamycin was demonstrated to
be attributable to changes in the levels of the p21 protein
because of a modest general decrease in translation brought
about by rapamycin (52). Whether PP4cs plays a role in the
control of translation and the regulation of p21 levels remains
to be investigated.
Further delineation of the interacting partners and supramo-
lecular architecture of the PP2A-type phosphatases should
greatly assist us in deciphering the roles that each of these
important proteins plays in various cellular processes. Given
that these enzymes play critical roles in DNA repair and tumor
promotion (4), a more intimate understanding of their regula-
tion and function should provide us with greater treatment
options for various types of cancers.
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